Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

This study has been completed.
Sponsor:
Information provided by:
Merrion Pharmaceuticals, LLC
ClinicalTrials.gov Identifier:
NCT00636740
First received: March 7, 2008
Last updated: February 19, 2009
Last verified: February 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2009
  Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)